Immunic (IMUX) Free Cash Flow (2013 - 2026)

Immunic has reported Free Cash Flow for 14 years, with the latest figure at -$17.3 million in Q1 2026.

• Quarterly Free Cash Flow rose 20.71% year-over-year to -$17.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$81.4 million (up 1.7% YoY) and the FY2025 annual result came in at -$86.0 million, down 1.1% from the prior year.
• Free Cash Flow grew to -$17.3 million in Q1 2026 per IMUX's latest filing, from -$19.3 million in the prior quarter.
• Over five years, Free Cash Flow peaked at -$13.7 million in Q3 2022 and troughed at -$24.6 million in Q2 2025.
• A 5-year average of -$19.1 million and a median of -$19.6 million in 2023 frame the typical range for Free Cash Flow.
• The sharpest annual moves came in 2022 and 2024: Free Cash Flow soared 45.59% in 2022, then tumbled 61.82% in 2024.
• Over 5 years, Free Cash Flow stood at -$15.1 million in 2022, then rose by 6.03% to -$14.2 million in 2023, then sank by 61.82% to -$23.0 million in 2024, then increased by 16.0% to -$19.3 million in 2025, then advanced by 10.31% to -$17.3 million in 2026.
• According to Business Quant data, Free Cash Flow over the past three periods registered -$17.3 million, -$19.3 million, and -$20.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.